TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06224608

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Mycobacterium Tuberculosis Fusion Protein (EEC)
Description: 1.0ml/bottle, containing 2.5μg/ml low dose, 5μg/ml medium dose, and 10μg/ml high dose of active ingredient.~Take 0.1ml and inject it into the center of the front 1/3 of the palm side of the forearm by the Montessori method Single dose administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Mycobacterium Tuberculosis Fusion Protein (EEC)
Description: 1.0ml/bottle, containing 2.5μg/ml low dose, 5μg/ml medium dose, and 10μg/ml high dose of active ingredient.~Take 0.1ml and inject it into the center of the front 1/3 of the palm side of the forearm by the Montessori method Single dose administration.
Study: NCT06421896

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: motivational Enhancement Therapy
Description: Motivational Enhancement Therapy (MET) is a systematic intervention that focuses on eliciting and strengthening a person's intrinsic motivation to change. MET is rooted in motivational interviewing principles, emphasizing empathy, autonomy, and the evocation of the patient's own motivations for change. The therapy typically involves several sessions where therapists help patients identify personal goals, explore ambivalence towards change, and develop actionable plans to achieve their desired outcomes.
Study: NCT05887817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finerenone
Description: Study participants will be instructed to take either finerenone or placebo orally once daily (preferably at approximately the same time every during the morning). For study participants with baseline eGFR less than 60mL/min/1.73 m2, the starting dose will be 10mg/day of finerenone (equivalent to 10mg/day in the placebo group), followed by 20 mg/day (equivalent to 20mg/day in the placebo group) approximately 4 weeks after the first dose, in accordance with the latest package insert. The dose should be increased to 20mg/day (equivalent to 20mg/day in the placebo group) in principle after 4 weeks from the start of the first dose, in accordance with the latest package insert. Study participants with a baseline eGFR of 60 mL/min/1.73m2 or higher will receive 20mg/day of finerenone (equivalent to 20mg/day in the placebo group) as the starting dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Study participants will be instructed to take either finerenone or placebo orally once daily (preferably at approximately the same time every during the morning). For study participants with baseline eGFR less than 60mL/min/1.73 m2, the starting dose will be 10mg/day of finerenone (equivalent to 10mg/day in the placebo group), followed by 20 mg/day (equivalent to 20mg/day in the placebo group) approximately 4 weeks after the first dose, in accordance with the latest package insert. The dose should be increased to 20mg/day (equivalent to 20mg/day in the placebo group) in principle after 4 weeks from the start of the first dose, in accordance with the latest package insert. Study participants with a baseline eGFR of 60 mL/min/1.73m2 or higher will receive 20mg/day of finerenone (equivalent to 20mg/day in the placebo group) as the starting dose.
Study: NCT04818138

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Narrowband UVB phototherapy
Description: Narrowband UVB phototherapy (full body) administered three times weekly according to individual clinical protocols.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Broadband UVB phototherapy
Description: Broadband UVB phototherapy (full body) administered three times weekly according to individual clinical protocols.
Study: NCT05521802

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: B-cell maturation antigen (BCMA) directed chimeric antigen receptor (CAR)-T cell
Description: Autologous 2nd generation BCMA-directed CAR-T cells, single infusion intravenously
Study: NCT06317896

Intervention type: DIAGNOSTIC_TEST
Intervention: circulating tumor cells
Description: blood sample and tissue specimen for circulating tumor cell and DNA will be done to patient with hepatocellular carcinoma
Study: NCT06109571

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Connections App
Description: The Connections app was developed for patients with substance use disorders or unhealthy substance use and adapted to include HIV support. For this study, it has been modified to provide additional resources to support patients engaged in HIV care. Connections' core features include agency-specific informational resources compiled in a resource center, patient self-monitoring through weekly check-in surveys, discussion rooms, and private messaging.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Connections App
Description: The Connections app was developed for patients with substance use disorders or unhealthy substance use and adapted to include HIV support. For this study, it has been modified to provide additional resources to support patients engaged in HIV care. Connections' core features include agency-specific informational resources compiled in a resource center, patient self-monitoring through weekly check-in surveys, discussion rooms, and private messaging.
Study: NCT05343026

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing aids
Description: As for screening the hearing and tinnitus testing, the measure typically comprises PTA, SRS, DPOAE, and several widely accepted standardized tinnitus questionnaires, including the THI for tinnitus severity and VAS for tinnitus loudness.
Study: NCT04974515

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: eXciteOSA
Description: eXciteOSA is a device for improving genioglossus endurance through electrical stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: eXciteOSA
Description: eXciteOSA is a device for improving genioglossus endurance through electrical stimulation
Study: NCT05285488

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: focused attention group
Description: focused attention group: adult subjects practicing focused attention meditation.~contemplation group: adult subjects practicing contemplation meditation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: focused attention group
Description: focused attention group: adult subjects practicing focused attention meditation.~contemplation group: adult subjects practicing contemplation meditation.
Study: NCT05882253

Intervention type: OTHER
Group type: OTHER
Intervention: Restricted Spectrum Imaging-Magnetic Resonance Imaging (RSI-MRI)
Description: An advanced imaging software that supports improved prostate cancer detection and diagnosis

Intervention type: OTHER
Group type: OTHER
Intervention: Restricted Spectrum Imaging-Magnetic Resonance Imaging (RSI-MRI)
Description: An advanced imaging software that supports improved prostate cancer detection and diagnosis

Intervention type: OTHER
Group type: OTHER
Intervention: Restricted Spectrum Imaging-Magnetic Resonance Imaging (RSI-MRI)
Description: An advanced imaging software that supports improved prostate cancer detection and diagnosis
Study: NCT05042037

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: (Microbial cell preparation) probiotics
Description: Lactobacillus acidophilus (107mg), Lactobacillus casei subsp (107mg), Lactobacillus lactis (107mg), Bifidobacterium bifidum (107mg), Bifidobacterium infantis (107mg) and Bifidobacterium longum (107mg)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo sachet with no microbial cell preparation
Study: NCT06288321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microdrop Mydrin-P
Description: Microdrop Mydrin-P consists of around one third of the standard Mydrin-P drop size. Drop volume measurement was performed using a precision weight scale (Sartorius) with accuracy up to 0.001g. The microdrop administration was conducted via attachment of a 16 gauge needle to a 1ml syringe.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard Mydrin-P
Description: Standard Mydrin-P is the standard mydriatic used for retinopathy of prematurity exam as per our local usual practice.
Study: NCT06016504

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Education
Description: Participate in an adaptive virtual consultation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: Participate in a non-adaptive virtual consultation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Informational Intervention
Description: Given information-only

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT04307329

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monalizumab
Description: Monalizumab 750 mg every two weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monalizumab
Description: Monalizumab 750 mg every two weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab 4 mg/kg every two weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab 4 mg/kg every two weeks
Study: NCT06303388

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bruegger,s Exercise
Description: Bruegger's Exercise protocol along with conventional Physiotherapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Egoscue Exercise
Description: Egoscue Exercise along with conventional Physiotherapy.
Study: NCT04940039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone 3 mg
Description: Participants will receive 3 mg oral risperidone tablet once daily for 3 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone Palmitate 50 mg eq.
Description: Participants will receive 50 mg eq. PP1M IM injection for at least 17 weeks (maximum 25 weeks).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone Palmitate 75 mg eq.
Description: Participants will receive 75 mg eq. PP1M IM injection for at least 17 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone Palmitate 100 mg eq.
Description: Participants will receive 100 mg eq. PP1M IM injection for at least 17 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone Palmitate 150 mg eq.
Description: Participants will receive 150 mg eq. PP1M IM injection for at least 17 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone Palmitate 175 mg eq.
Description: Participants will receive 175 mg eq. PP3M IM injection up to 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone Palmitate 263 mg eq.
Description: Participants will receive 263 mg eq. PP3M IM injection up to 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone Palmitate 350 mg eq.
Description: Participants will receive 350 mg eq. PP3M IM injection up to 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone Palmitate 525 mg eq.
Description: Participants will receive 525 mg eq. PP3M IM injection up to 24 weeks.
Study: NCT06464003

Intervention type: OTHER
Intervention: Questionnaire
Description: Malocclusion impact questionnaire

Intervention type: OTHER
Intervention: Questionnaire
Description: Malocclusion impact questionnaire

Intervention type: OTHER
Intervention: Questionnaire
Description: Malocclusion impact questionnaire
Study: NCT03584113

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Video assisted thorascopic decortication
Description: Video assisted thorascopic decortication surgery as primary intervention for empyema

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interventional radiology guided chest tube insertion with MIST2 trial fibrinolytics
Description: Image guided chest tube insertion by IVR with intrapleural fibrinolytics (six doses of dornase \[5mg\] and alteplase \[10mg\] Q12hours).
Study: NCT05434962

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac resynchronization therapy
Description: Standard BiV-CRT The CRT-P/CRT-D device and leads should be implanted according to the physician's manual provided with the devices. Only locally approved Medtronic CRT-P/CRT-D generators will be used during the study. The LV lead should be implanted at a lateral or posterolateral CS branch in a basal or mid ventricular position confirmed by ortogonal fluoroscopic views (RAO and LAO 40º). Acceptable LV pacing threshold should be \<3V@0,5ms and phrenic nerve stimulation (PNS) margin should be \>1V with respect to the pacing threshold.~LBBAP-CRT The CRT-P/CRT-D device and leads should be implanted according to the physician's standard practice. Only locally approved Medtronic CRT-P/CRT-D generators will be used during the study. During the implant procedure lead impedances, pacing and sensing parameters will be measured using a pacing system analyzer (PSA). For LBBAP, the Medtronic 3830 lead will be used. Acceptable LBBAP threshold should be \<2,5V@0,5ms

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy
Description: Standard BiV-CRT The CRT-P/CRT-D device and leads should be implanted according to the physician's manual provided with the devices. Only locally approved Medtronic CRT-P/CRT-D generators will be used during the study. The LV lead should be implanted at a lateral or posterolateral CS branch in a basal or mid ventricular position confirmed by ortogonal fluoroscopic views (RAO and LAO 40º). Acceptable LV pacing threshold should be \<3V@0,5ms and phrenic nerve stimulation (PNS) margin should be \>1V with respect to the pacing threshold.~LBBAP-CRT The CRT-P/CRT-D device and leads should be implanted according to the physician's standard practice. Only locally approved Medtronic CRT-P/CRT-D generators will be used during the study. During the implant procedure lead impedances, pacing and sensing parameters will be measured using a pacing system analyzer (PSA). For LBBAP, the Medtronic 3830 lead will be used. Acceptable LBBAP threshold should be \<2,5V@0,5ms
Study: NCT05447533

Intervention type: OTHER
Group type: OTHER
Intervention: Comprehensive geriatric assessment (CGA)
Description: Within 5 weekdays from date of randomization (not included) a standardized CGA with a tailor-made intervention will be performed in the allocated ward or at home by a geriatric team. Bedside Multidimensional Prognostic Index (MPI) will be performed.~A geriatric Clostridioides difficile infection checklist will be performed by local geriatrician and secure an early assessment of CDI and treatment strategy.~When indication: pre-treatment with vancomycin 125 mg x 4. Routine biochemical analyses for patients with Clostridioides difficile infection.~Evaluation of indication for faecal microbiota transplantation (FMT).~Criteria for FMT rely on the geriatric assessment and will be considered for the patient if the patient fulfil one of the following:~1. Severe index, recurrent or refractory CDI as defined by national clinical guidelines or~2. High risk patient according to CGA at first visit. High risk patient is defined frailty grade MPI-2 (moderate) or MPI-3 (severe).

Intervention type: OTHER
Group type: OTHER
Intervention: Continued geriatric care
Description: Continued specialized geriatric care through 8 weeks of follow-up. Minimum of follow-up is 8 weeks from last FMT or start of vancomycin/fidaxomicin treatment.~Tailormade telephone contacts and/or visits in case of clinical exacerbation. Performed by local geriatric teams.~The geriatric department remains responsible for the CDI during 8 weeks of follow-up or until cured.

Intervention type: OTHER
Group type: OTHER
Intervention: Faecal microbiota transplantation (FMT)
Description: When clinical indication for FMT, this will be delivered as 15-25 capsules (\~ 50 grams of donor faeces from one thoroughly screened healthy donor). If the patient is not admitted to hospital, FMT will be de-livered as home treatment via regional geriatric team or project manager and project nurse. If the patient has dysphagia diagnosed by dysphagia screening or carries a nasogastric tube, vancomycin and FMT can be delivered by naso-jejunal tube (Bengmark 10 Fr, Nutricia), requiring a referral to the Radiology department for verification of duodenal/jejunal tube placement. If available in the specific department, placement can be controlled via mobile x-ray.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard care: Patients are not contacted by the geriatric team. They receive usual treatment at the treating physician's discretion.
Study: NCT05024994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7820
Description: 100mg of E7820 QD
Study: NCT04496986

Intervention type: DIAGNOSTIC_TEST
Intervention: Fiberoptic Endoscopic Evaluation of Swallowing
Description: This procedure involves inserting a flexible laryngoscope that contains a light source and video camera on the end through the open passage of the nose towards the back of the throat in order to visualize the swallowing mechanism.

Intervention type: DIAGNOSTIC_TEST
Intervention: Fiberoptic Endoscopic Evaluation of Swallowing
Description: This procedure involves inserting a flexible laryngoscope that contains a light source and video camera on the end through the open passage of the nose towards the back of the throat in order to visualize the swallowing mechanism.

Intervention type: DIAGNOSTIC_TEST
Intervention: Simultaneous FEES and Videofluoroscopy instrumental swallowing exam
Description: This procedure involves inserting a flexible laryngoscope that contains a light source and video camera on the end through the open passage of the nose towards the back of the throat in order to visualize the swallowing mechanism. The participant will be asked to perform some voicing tasks, once completed, a videofluoroscopic swallowing exam will occur at the same time. This is like moving x-ray of the participant swallowing foods and liquids (barium).

Intervention type: OTHER
Intervention: Voluntary Cough Peak Expiratory Flow (PEF) Testing
Description: Cough PEF will be performed to index a participant's physiologic airway defense capacity and strength. Testing will occur with the participant seated upright at 90 degrees using an analog peak flow meter with a one-way expiratory valve that prevents a participant from breathing air in from the device to reduce contamination.

Intervention type: OTHER
Intervention: Reflex Cough Screen
Description: Participants will be seated upright and administered reflex cough testing via a disposable adult aerosol mask with an attached nebulizer that contains a solution to elicit a cough response.

Intervention type: OTHER
Intervention: Lingual Pressure Testing
Description: Lingual strength will be evaluated using the Iowa Oral Pressure Instrument (IOPI). Participants will be seated upright, and the SLP will place the IOPI air-filled sensing bulb in the midline anterior position on the participant's tongue, posterior to the alveolar ridge.

Intervention type: DIAGNOSTIC_TEST
Intervention: Speech Testing
Description: Speech assessment will occur with the participant comfortably seated headset microphone with a lapel windscreen connected to a TASCAM DR40 to allow for high-quality audio recordings. Individuals will be asked to perform two maximal performance speech tasks that include vowel prolongation of /a/, and a Diadochokinetic (DDK) rate task to examine SMR for production of the word buttercup.
Study: NCT06334302

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Omega Galil Hazelnut Chocolate Spread O'Sweet Spread
Description: Omega Galil O'Sweet hazelnut cocoa spread is composed of 8% sucrose, 26% MCT oil, 6% cocoa butter, 6% cocoa powder, 10% Hazelnut paste, 24% fibers, 13% rice flour. It contains a total of 27.3 gram carbohydrates/ 100gram, 520 kcals/100 grams, and very low estimated GL according to healthy adults

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Control-Nutella hazelnut cocoa spread
Description: Nutella hazelnut cocoa spread is composed of 56% sugar, 30% vegetable fat, 13% Hazelnut paste, milk powder (8.7%), and cocoa powder (7.4%), containing a total of 57.5 grams carbohydrates /100grams, 532 kcals/100 grams, and an estimated GL of 4
Study: NCT04723862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: Spironolactone is an androgen-receptor blocker commonly used (off-label) for hyperandrogenism. The spironolactone dose will be 50 mg taken orally twice daily (for two weeks before admission to the Clinical Research Unit).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo contains only inert ingredients and is not expected to exert any direct physiological effects.
Study: NCT05381987

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Radial shockwave therapy
Description: Shockwave Storz Medical device, Doulith SD1, Tower (BT)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radial shockwave therapy
Description: Shockwave Storz Medical device, Doulith SD1, Tower (BT)
Study: NCT05649033

Intervention type: OTHER
Intervention: data collection
Description: Work-related stress evaluation
Study: NCT06085911

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: One day course
Description: a physical one-day course at the Covid rehabilitation clinic. During these six hours, general information about rehabilitation principals will be given. Theory about three 15 focus areas of importance will be presented; daily routine, importance of being active and cognitive training. They will meet others with similar problems and will be given an opportunity to exchange experience. 8-10 patients will participate in the group.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual follow-ups
Description: the patient will meet a therapist in a physical consultation at the Covid rehabilitation clinic lasting for 1.5 hours. Together they will in detail map out symptoms and impairment of function in the patient's life. Together the patient and the therapist will create plan to address these problems consisting of tailored home-based exercises within the three focus areas. Tree follow-up consultations will be given.
Study: NCT06104202

Intervention type: OTHER
Intervention: Early Maladaptive Schemas
Description: Compare profiles of maladaptive early patterns using scores :~* Young Schema Questionnaire Short form~* Maslach Burnout Inventory~* Montgomery-Asberg depression rating Scale~* White Bear Suppression Inventory

Intervention type: OTHER
Intervention: Early Maladaptive Schemas
Description: Compare profiles of maladaptive early patterns using scores :~* Young Schema Questionnaire Short form~* Maslach Burnout Inventory~* Montgomery-Asberg depression rating Scale~* White Bear Suppression Inventory

Intervention type: OTHER
Intervention: Early Maladaptive Schemas
Description: Compare profiles of maladaptive early patterns using scores :~* Young Schema Questionnaire Short form~* Maslach Burnout Inventory~* Montgomery-Asberg depression rating Scale~* White Bear Suppression Inventory